Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01161771
First received: July 6, 2010
Last updated: July 17, 2012
Last verified: July 2012

July 6, 2010
July 17, 2012
May 2010
December 2010   (final data collection date for primary outcome measure)
The Percentage of Subjects at Month 3 With Corneal Sensitivity < 50 Millimeters (mm) at Any of the Locations Measured [ Time Frame: Month 3 ] [ Designated as safety issue: No ]
The percentage of subjects at month 3 with corneal sensitivity < 50 mm at any of the locations measured. Corneal sensitivity is evaluated by using a nylon filament to measure the capability of the cornea (clear front portion of the eye) to respond to touch. The longest filament length at which a minimum of the 3 out of 5 stimulus applications produce a positive response from the subject was the corneal touch threshold (sensitivity). Measurements were taken at 5 different locations in each cornea.
Corneal Sensation [ Time Frame: Month 3 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01161771 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
    Change from baseline in OSDI total score at month 3. The OSDI is a 12-question survey for subjects to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.
  • Change From Baseline in Corneal Staining at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
    Change from baseline in corneal staining at month 3. The cornea is the transparent front part of the eye which covers the iris and pupil. Corneal staining following administration of fluorescein dye in the eye is graded using a 6-point scale (0= no staining, 5 = severe staining) over 5 areas of the clear central part of the eye for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A positive number change from baseline represents an increase in corneal staining (worsening of dry eye).
  • Change From Baseline in Conjunctival Staining at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
    Change from baseline in conjunctival staining severity score at month 3. The conjunctiva is the clear membrane covering the white surface of the eye. Conjunctival staining following ocular administration of lissamine green dye was graded using a 6-point scale (0= no staining, 5= severe staining) over 6 areas of the white part of the eye for a minimum score of 0 and a maximum score of 30. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of conjunctival staining (improvement)
  • Change From Baseline in Tear Break-Up Time at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
    Change from baseline in tear break-up time (TBUT) at month 3. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A negative number change from baseline indicates a decrease in TBUT (worsening).
  • Change From Baseline in Schirmer's Test at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
    Change from baseline in Schirmer's Test result at month 3. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement).
  • Ocular Surface Disease Index Questionnaire [ Time Frame: Month 3 ] [ Designated as safety issue: No ]
  • Corneal and Conjunctival Staining [ Time Frame: Month 3 ] [ Designated as safety issue: No ]
  • Tear Breakup Time [ Time Frame: Month 3 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye
Not Provided

This is a multicenter evaluation of the effects of the cataract extraction and limbal relaxing incisions (LRI) on corneal sensation and dry eye signs and symptoms.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients undergoing cataract extraction and limbal relaxing incision

Dry Eye
Procedure: Cataract Surgery and Limbal relaxing incision
Cataract extraction and limbal-relaxing incisions
Patients with cataract and corneal astigmatism
Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
Intervention: Procedure: Cataract Surgery and Limbal relaxing incision
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient scheduled to undergo clear corneal cataract extraction with planned limbal relaxing incision for correction of a corneal astigmatism

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Have undergone refractive surgery or any surgery involving a limbal or corneal incision
  • Use of topical cyclosporine (Restasis) within three months of baseline/randomization visit
  • Temporary or permanent occlusion of the lacrimal puncta
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01161771
MA-RES-09-004
No
Allergan
Allergan
Not Provided
Study Director: Medical Director Allergan
Allergan
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP